Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September
09/08/2020 - 07:05 AM
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.
Dr. Alon Seri-Levy, Sol-Gel’s Chief Executive Officer, will provide an overview of the Company and give a business update. A live webcast of the presentation will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com . An archived webcast recording of the event will be available on the website for approximately 30 days.
H.C. Wainwright Healthcare Conference Speaker: Gilad Mamlok, Chief Financial Officer Date: September 15, 2020 Time: 10:00 AM ET Cantor Fitzgerald Virtual Global Healthcare Conference – Fireside Chat Speakers: Dr. Alon Seri-Levy, Chief Executive Officer Gilad Mamlok, Chief Financial Officer John Vieira, U.S. Head of Commercialization Date: September 17, 2020 Time: 8:40 AM ET
About Sol-Gel Technologies Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com .
For further information, please contact: Sol-Gel Contact: Gilad Mamlok Chief Financial Officer +972-8-9313433
Investor Contact: Lee Stern Solebury Trout +1-917-312-5998 lstern@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
SLGL Rankings
#5200 Ranked by Stock Gains
SLGL Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
Israel
City
7 Golda Meir
About SLGL
sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th